Blood stage vaccines for Plasmodium falciparum: Current status and the way forward

Human Vaccines

Volumn 6, Issue 8, 2010, Pages 627-634

  Ellis, Ruth D ^a   Sagara, Issaka ^a   Doumbo, Ogobara ^a   Wu, Yimin ^a  

^a UNIVERSITY OF BAMAKO   (Mali)

Author keywords

Blood stage; Falciparum; Malaria; Merozoite; Vaccine

Indexed keywords

ADJUVANT; AGATOLIMOD; ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; MALARIA VACCINE; PARASITE ANTIGEN; RECOMBINANT PROTEIN; SYNTHETIC PEPTIDE; VIRUS VACCINE;

ADULT; ANTIBODY TITER; BLOOD; CHILD; DISEASE TRANSMISSION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SAFETY; ERYTHROCYTE; HUMAN; HYDROGEL; IMMUNOGENICITY; MALARIA; MALARIA FALCIPARUM; MEROZOITE; NONHUMAN; PARASITE DEVELOPMENT; PLASMODIUM FALCIPARUM; REVIEW; TREATMENT OUTCOME; VACCINATION; VACCINE PRODUCTION;

EID: 77956637982     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.8.11446     Document Type: Review

References (71)

1. Roberts L, Enserink M. Did they really say... eradication? Science 2007; 318:1544-5.
2. WHO publication. World Malaria report 2009; http://whqlibdoc.who.int/ publications/2009/9789241563901-eng.pdf.
3. Kleinschmidt I, Schwabe C, Benavente L, Torrez M, Ridl FC Segura JL, et al. Marked Increase in child survival after four years of intensive malaria control. AJTMH 2009; 80:882-8.
4. Bhattarai A, Ali AS, Kachur SP, Mårtensson A, Abbas AK, Khatib R, et al. Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Med 2007; 4:309.
5. Barnes KI, Chanda P, Ab Barnabas G. Impact of the large-scale deployment of artemether/lumefantrine on the malaria disease burden in Africa: case studies of South Africa, Zambia and Ethiopia. Malar J 2009; 8:8.
6. Cohen S, McGregor IA. Carrington (1961) Gamma-globulin and acquired immunity to human malaria. Nature 192:733-7.
7. Sabchareon A, Burnouf T, Ouattara D, Attanath P, Bouharoun-Tayoun H, et al. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg 1991; 45:297-308.
8. Doolan DS, Cobano C, Baird JK. Acquired Immunity to Malaria. Clin Microbiol Rev 2009; 22:13-36.
9. Pombo DJ, Lawrence G, Hirunpetcharat C, Rzepczyk C, Bryden M, Cloonan N, Anderson K, et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 2002; 360:610-7.
10. Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, van Gemert GJ, et al. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 2009; 361:468-77.
11. Guinovart C, Aponte JJ, Sacarlal J, Aide P, Leach A, Bassat Q, et al. Insights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a Phase IIb trial in Mozambican children. PLOS One 2009; 4:5165. doi:10.1371/journal. pone.0005165.
12. Malkin EM, Diemert DJ, McArthur JH, Perreault JR, Miles AP, Giersing BK, et al. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect Immun 2005; 73:3677-85.
13. Dicko A, Sagara I, Ellis RD, Miura K, Guindo O, Kamate B, et al. Phase 1 Study of a Combination AMA1 Blood Stage Malaria Vaccine in Malian Children. PLoS One 2008; 3:1563.
14. Dicko A, Diemert DJ, Sagara I, Sogoba M, Niambele MB, Assadou MH, et al. Impact of a Plasmodium falciparum AMA1 Vaccine on Antibody Responses in Adult Malians. PLoS ONE 2007; 2:1045.
15. Sagara I, Dicko A, Ellis RD, Fay MP, Diawara Sory, Assadou MH, et al. A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine 2009; 27:3090-8.
16. Mullen GED, Ellis RD, Miura K, Malkin E, Nolan C, Hay M, et al. Phase 1 Trial of AMA1-C1/Alhydrogel plus CPG 7909: An Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria. PLoS ONE 2008; 3:2940.
17. Ellis RD, Mullen GED, Pierce M, Martin LB, Miura K, Fay MP, et al. A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/ Alhydrogel® with CPG 7909, using two different formulations and dosing intervals. Vaccine 2009; 27:4104-9.
18. Sagara I, Ellis RD, Dicko A, Niambele MB, Kamate B, Guindo O, et al. A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults. Vaccine 2009; 27:7292-8.
19. Polhemus ME, Magill AJ, Cummings JF, Kester KE, Ockenhouse CF, Lanar DE, et al. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research. Vaccine 2007; 25:4203-12.
20. Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Kone AK, Guindo AB, et al. Safety and Immunogenicity of an AMA-1 Malaria Vaccine in Malian Adults: Results of a Phase 1 Randomized Controlled Trial. PLoS ONE 2008; 3:1465.
21. Thera M, Doumbo OK, Coulibaly D, Laurens MB, Kone AK, Guindo AB, et al. Safety and Immunogenicity of an AMA-1 Malaria Vaccine in Malian Children: Results of a Phase 1 Randomized Controlled Trial. PLoS One, in press.
22. Pierce MP, Ellis RD, Martin LB, Malkin E, Tierney E, Miura K, et al. Phase 1 Safety and Immunogenicity Trial of the Plasmodium falciparum Blood-Stage Malaria Vaccine AMA1-C1/ISA 720 in Australian Adults. Vaccine, in press.
23. Saul A, Lawrence G, Allworth A, Elliott S, Anderson K, Rzepczyk C, et al. A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant. Vaccine 2005; 23:3076-83.
24. Roestenberg M, Remarque E, de Jonge E, Hermsen R, Blythman H, Leroy O, et al. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS ONE 2008; 3:3960.
25. Spring MD, Cummings JF, Ockenhouse CF, Dutta S, Reidler R, Angov E, et al. Phase 1/2a Study of the Malaria Vaccine Candidate Apical Membrane Antigen-1 (AMA-1) Administered in Adjuvant System AS01B or AS02A. PLoS ONE 2009; 4:5254.
26. Hu J, Chen Z, Gu J, Wan M, Shen Q, Kieny MP, et al. Safety and Immunogenicty of a Malaria Vaccine, Plasmodium falciparum AMA-1/MSP-1 Chimeric Protein Formulated in Montanide ISA 720 in Health Adults. PLoS One 2008; 3:1952.
27. Genton B, Pluschke G, Degen L, Kammer AR, Westerfeld N, Okitsu SL, et al. A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome- formulated synthetic peptides in healthy adult volunteers. PLoS ONE 2007; 2:1018.
28. Thompson FM, Porter DW, Okitsu SL, Westerfeld N, Vogel D, Todryk S, et al. Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. PLoS ONE 2008; 3:1493.
29. 42) Vaccines for Plasmodium falciparum Malaria. PLOS Clin Trial 2007; 2:12.
30. 42-C1/ Alhydrogel with and without CPG 7909 in Malaria Naïve Adults. PLoS One, in press.
31. Ockenhouse CF, Angov E, Kester KE, Diggs C, Soisson L, Cummings JF, et al. Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. Vaccine 2006r; 24:3009-17.
32. Stoute JA, Gombe J, Withers MR, Siangla J, McKinney D, Onyango M, et al. Phase 1 randomized doubleblind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. Vaccine 2007; 25:176-84.
33. Ogutu BR, Apollo OJ, McKinney D, Okoth W, Siangla J, Dubovsky F, et al. Blood Stage Malaria Vaccine Eliciting High Antigen-Specific Antibody Concentrations Confers No Protection to Young Children in western Kenya. PLoS ONE 2009; 4:4708.
34. Withers MR, McKinney D, Ogutu BR, Waitumbi JN, Milman JB, Apollo OJ, et al. Safety and Reactogenicity of an MSP-1 Malaria Vaccine Candidate: A Randomized Phase Ib Dose-Escalation Trial in Kenyan. PLOS Clin Trial 2006; 1:32.
35. Saul A, Lawrence G, Smillie A, et al. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. Vaccine 1999; 17:3145-59.
36. Lawrence G, Cheng QQ, Reed C, Taylor D, Stowers A, Cloonan N, et al. Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers. Vaccine 2000; 18:1925-31. (Pubitemid 30122856)
37. Genton B, Al-Yaman F, Anders R, Saul A, Brown G, Pye D, et al. Safety and immunogenicity of a threecomponent blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea. Vaccine 2000; 18:2504-11.
38. Genton B, Al-Yaman F, Betuela I, Anders RF, Saul A, Baea K, et al. Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children. Vaccine 2003; 22:30-41. (Pubitemid 37357150)
39. Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A, et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. Am J Infect Dis 2002; 185:820-7.
40. Ockenhouse CF, Sun PF, Lanar DE, Wellde BT, Hall BT, Kester K, et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis 1998; 177:1664-73.
41. Audran R, Cachat M, Lurati F, Soe S, Leroy O, Corradin G, et al. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect Immun 2005; 73:8017-26. (Pubitemid 41740288)
42. Sirima SB, Nébié I, Ouédraogo A, Tiono AB, Konaté AT, Gansané A, et al. Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa. Vaccine 2007; 25:2723-32. (Pubitemid 46400921)
43. Lusingu JP, Gesase S, Msham S, Francis F, Lemnge M, Seth M, et al. Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months. Malar J 2009; 8:163.
44. Sirima SB, Tiono AB, Ouédraogo A, Diarra A, Ouédraogo AL, Yaro JB, et al. Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children. PLoS One 2009; 4:7549.
45. Hermsen CC, Verhage DF, Telgt DS, Teelen K, Bousema JT, Roestenberg M, et al. Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial. Vaccine 2007; 25:2930-40. (Pubitemid 46412561)
46. Esen M, Kremsner PG, Schleucher R, Gässler M, Imoukhuede EB, Imbault N, et al. Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate. Vaccine 2009; 27:6862-8.
47. Horii T. Malaria Vaccine. Nippon Rinsho 2008; 66:1990-8.
48. Richards JS, Beeson JG. The future for blood-stage vaccines against malaria. Immunol Cell Biol 2009; 87:377-90.
49. Silvie O, Franetich JF, Charrin S, et al. A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J Biol chem 2004; 279:9490-6. (Pubitemid 38296016)
50. Bergmann-Leitner ES, Duncan EH, Mullen GE, Burge JR, Khan F, Long CA, et al. Critical evaluation of different methods for measuring the functional activity of antibodies against malaria blood stage antigens. Am J Trop Med Hyg 2006; 75:437-42. (Pubitemid 46941302)
51. Takala SL, Coulibaly D, Thera MA, Batchelor AH, Cummings MP, Escalante AA, et al. Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. Sci Transl Med 2009; 1:2-5. DOI:10.1126/scitranslmed.3000257.
52. Duan J, Mu J, Thera MA, Joy D, Kosakovsky Pond SL, Diemert D, et al. Population structure of the genes encoding the polymorphic Plasmodium falciparum apical membrane antigen 1: implications for vaccine design. Proc Natl Acad Sci USA 2008; 105:7857-62. (Pubitemid 351872728)
53. Remarque EJ, Faber BW, Kocken CH, Thomas AW. A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits. Infect Immun 2008; 76:2660-70.
54. Dutta S, Dlugosz LS, Clayton JW, Pool CD, Haynes JD, Gasser RA, 3rd, et al. Alanine mutagenesis of the primary antigenic escape residue cluster (C1) of Apical Membrane Antigen-1. Infect Immun 2009; Epub ahead of print.
55. 19, MSP3 and GLURP with protection from clinical malaria in Ghanaian children. Malaria J 2008; 7:doi:10.1186/1475-2875-7-142.
56. Roussilhon C, Oeuvray C, Muller-Graf C, Tall A, Rogier C, et al. Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to Merozoite Surface Protein 3. PLoS Med 2007; 4:320.
57. Osier FA, Fegan G, Polley SD, Murungi L, Verra F, et al. Breadth and magnitude of antibody responses to multiple plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun 2008; 76:2240-8.
58. Iriemenam NC, Khirelsied AH, Nasr A, ElGhazali G, Giha HA, et al. Antibody responses to a panel of Plasmodium falciparum malaria blood-stage antigens in relation to clinical disease outcome in Sudan. Vaccine 2009; 27:62-71.
59. Wang L, Richie TL, Stowers A, Nhan DH, Coppel RL. Naturally acquired antibody responses to Plasmodium falciparum merozoite surface protein 4 in a population living in an area of endemicity in Vietnam. Infect Immun 2001; 69:4390-7. (Pubitemid 32574437)
60. Oleinikov AV, Francis SE, Dorfman JR, Rossnagle E, Balcaitis S, Getz T, et al. VAR2CSA domains expressed in Escherichia coli induce cross-reactive antibodies to native protein. J Infect Dis 2008; 197:1119-23. (Pubitemid 351590047)
61. Avril M, Hathaway MJ, Cartwright MM, Gose SO, Narum DL, et al. Optimizing expression of the pregnancy malaria vaccine candidate, VAR2CSA in Pichia pastoris. Malar J 2009; 8:143.
62. Pichyangkul S, Tongtawe P, Kum-Arb U, Yongvanitchit K, Gettayacamin M, Hollingdale MR, et al. Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys. Vaccine 2009; 28:452-62.
63. McCarthy JS, Good MF. Whole parasite blood stage malaria vaccines: A convergence of evidence. Hum Vaccin 2010; 6:Epub ahead of print.
64. Doolan DL, Mu Y, Unal B, Sundaresh S, Hirst S, Valdez C, et al. Profiling humoral immune responses to P. falciparum infection with protein microarrays. Proteomics 2008; 8:4680-94.
65. Dutta S, Sullivan JS, Grady KK, Haynes JD, Komisar J, Batchelor AH, et al. High antibody titer against apical membrane antigen-1 is required to protect against malaria in the aotus model. PLoS One 2009; 4:8138.
66. Ballou WR. The development of the RTS,S malaria vaccine candidate: challenges and lessons. Parasite Immunol 2009; 31:492-500.
67. Luke TC, Hoffman SL. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine. J Exp Biol 2003; 206:3803-8.
68. Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One 2008; 3:2636.
69. Sanderson F, Andrews L, Douglas AD, Hunt-Cooke A, Bejon P, et al. Blood-stage challenge for malaria vaccine efficacy trials: a pilot study with discussion of safety and potential value. Am J Trop Med Hyg 2008; 78:878-83. (Pubitemid 351967803)
70. Moorthy VS, Diggs C, Ferro S, Good MF, Herrera S, et al. Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18-19 March 2009, Bethesda MD, USA. Vaccine 2009; 27:5719-25.
71. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 2002; 419:498-511.